Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
Anti-Her2 II / Anti-Her2 IV Bi-specific antibody ADC | Bioconjugates | Oncology/Cancer | Solid tumor | Preclinical | Global |
Her2xCD3 BsAb | Bispecific antibody | Oncology/Cancer | HER2-positive Cancer | Phase I | Global |
5e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Her2, His Tag (Cat. No. HE2-HA2H9) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
Herceptin captured on Protein A Chip can bind Biotinylated Human Her2, His, Avitag, premium grade (Cat. No. HE2-H82E2) with an affinity constant of 30.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Trastuzumab biosimilar (AryoGen Pharmed) | Approved | Aryogen Biopharma | AryoTrust | Stomach Neoplasms; Breast Neoplasms | Details | |||||
Trastuzumab/Hyaluronidase | Approved | Genentech Inc | Herceptin Hylecta | United States | Breast Neoplasms | Genentech Inc | 2019-02-28 | Breast Neoplasms | Details | |
Trastuzumab biosimilar (Dr. Reddy's Laboratories) | Approved | Dr Reddy's Laboratories Ltd | Hervycta | India | Breast Neoplasms | Dr Reddy's Laboratories Ltd | 2018-07-26 | Breast Neoplasms | Details | |
Trastuzumab biosimilar (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Breast Neoplasms | Details | ||||||
Trastuzumab biosimilar (AXXO) | Approved | Axxo | Breast Neoplasms | Details | ||||||
Trastuzumab biosimilar (Reliance Life Sciences) | R-TPR-016 | Approved | Reliance Life Sciences | TrastuRel | India | Breast Neoplasms | Reliance Life Sciences | 2015-01-01 | Breast Neoplasms | Details |
Trastuzumab biosimilar (Zydus) | Approved | Zydus Cadila | Vivitra | India | Breast Neoplasms | Zydus Cadila | 2016-01-01 | Breast Neoplasms | Details | |
Trastuzumab biosimilar (Biocad) | BCD-022 | Approved | Biocad | HERtiCAD | Russian Federation | Breast Neoplasms | Biocad | 2016-01-01 | Breast Neoplasms | Details |
Trastuzumab emtansine biosimilar (Zydus Cadila) | ZRC-3256 | Approved | Zydus Cadila | Ujvira | India | Breast Neoplasms | Zydus Cadila | 2021-05-24 | Breast Neoplasms | Details |
Trastuzumab/Pertuzumab | RO-7198574; RG-6264 | Approved | F. Hoffmann-La Roche Ltd | Phesgo | EU | Breast Neoplasms | Roche Registration Gmbh | 2020-06-29 | Breast Neoplasms; Metastatic breast cancer | Details |
Trastuzumab biosimilar (Shanghai Henlius Biotech) | HLX-02 | Approved | Shanghai Henlius Biotech Co Ltd | Zercepac, 汉曲优 | Australia | Stomach Neoplasms; Breast Neoplasms | Cipla Australia Pty Ltd | 2020-07-27 | Stomach Neoplasms; Neoplasms; Breast Neoplasms | Details |
Ado-trastuzumab emtansine | RG-3502; R-3502; T-DM1; PRO-132365; RO-5304020 | Approved | Genentech Inc | Kadcyla, 赫赛莱 | Mainland China | Breast Neoplasms | Roche Pharma (Schweiz) Ag | 2013-02-22 | Solid tumours; Hematologic Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Breast Neoplasms; Cholangiocarcinoma; Urologic Neoplasms; Lung Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Tucatinib | ARRY-380; ONT-380; MK-7119 | Approved | Array Biopharma | Tukysa | EU | Breast Neoplasms | Seagen Netherlands Bv | 2020-04-17 | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Meningeal Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis | Details |
Disitamab Vedotin | RC-48-ADC; RC48-ADC; RC-48 | Approved | RemeGen Co Ltd | 爱地希 | Mainland China | Carcinoma, Transitional Cell | RemeGen Co Ltd | 2021-06-08 | Liver Neoplasms; Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Genital Diseases, Female; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Genital Neoplasms, Female; Breast Diseases; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Dacomitinib | PF-299; PF-804; PF-299804; PF-00299804; PF-00299804-3; PF-00299804-03 | Approved | Pfizer Inc | Vizimpro | Mainland China | Carcinoma, Non-Small-Cell Lung | Pfizer Europe Ma Eeig | 2018-09-27 | Colorectal Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Penile Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Head and Neck Neoplasms; Brain Neoplasms; Carcinoma, Large Cell; Liver Diseases; Glioblastoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours | Details |
Pertuzumab | RG-1273; RO-4368451-F01; rhuMab-2C4; RO-4368451; R-1273 | Approved | Genentech Inc | Perjeta, Omnitarg | Mainland China | Breast Neoplasms | Roche Pharma (Schweiz) Ag | 2012-06-08 | Neuroendocrine Tumors; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Fallopian Tube Neoplasms; Multiple Endocrine Neoplasia; Carcinoma, Neuroendocrine; Peritoneal Neoplasms; Neuroblastoma; Prostatic Neoplasms; Breast Neoplasms; Adrenal Gland Neoplasms; Ovarian Neoplasms; Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Rectal Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours | Details |
Trastuzumab biosimilar (Biocon/Mylan) | Bmab-200; Myl-1401O; HerMyl-1401O | Approved | Biocon Ltd, Mylan Nv | CANMAb, Ogivri, Zedora, Hertraz | EU | Breast Neoplasms; Stomach Neoplasms | Viatris Ltd | 2013-01-01 | Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Esophageal adenocarcinoma; Adenocarcinoma; Uterine Cervical Neoplasms | Details |
Trastuzumab biosimilar (Pfizer) | PF-5280014; PF-05280014 | Approved | Pfizer Inc | Trazimera | Japan | Breast Neoplasms; Stomach Neoplasms | Pfizer Inc | 2018-07-26 | Urinary Bladder Neoplasms; Melanoma; Uterine Cervical Neoplasms; Thyroid Neoplasms; Esophageal adenocarcinoma; Endometrial Neoplasms; Uterine Neoplasms; Lung Neoplasms; Glioma; Lymphoma; Colorectal Neoplasms; Cholangiocarcinoma; Prostatic Neoplasms; Breast Neoplasms; Liver Neoplasms; Multiple Myeloma; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
Afatinib Dimaleate | BIBW-2992; BIBW-2992-MA2 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Gilotrif, Tomtovok, 吉泰瑞, Tovok, Giotrif | Mainland China | Carcinoma, Non-Small-Cell Lung | Boehringer Ingelheim International Gmbh | 2013-07-12 | Lymphoma; Prostatic Neoplasms; Brain Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Ureteral Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Breast Neoplasms; Uterine Neoplasms; Glioma; Esophageal Squamous Cell Carcinoma; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Hematologic Neoplasms; Liver Diseases; Urinary Bladder Neoplasms; Chordoma; Multiple Myeloma; Neuroectodermal Tumors; Glioblastoma; Neoplasms; Neoplasms, Squamous Cell; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Rhabdomyosarcoma; Head and Neck Neoplasms; Solid tumours | Details |
Fam-trastuzumab deruxtecan | DS-8201a; DS-8201 | Approved | Daiichi Sankyo Co Ltd | Enhertu | United States | Carcinoma, Non-Small-Cell Lung | Daiichi Sankyo Co Ltd | 2019-12-20 | Osteosarcoma; Uterine Cervical Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Brain metastases; Metastatic breast cancer; Meningeal Neoplasms; Colorectal Neoplasms; Ovarian Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Neoplasms; Neoplasms, Glandular and Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Biliary Tract Neoplasms | Details |
Trastuzumab | R-597; RO45-2317; Anti-HER2/neu-MAb; huMAb4D5-8; RG-597; MKC-454 | Approved | Genentech Inc | Herceptin, 赫赛汀 | Mainland China | Stomach Neoplasms | Roche Pharma (Schweiz) Ag | 1998-09-25 | Sarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Lung Neoplasms; Metastatic breast cancer; Vulvar Diseases; Endometrial Neoplasms; Urologic Neoplasms; Carcinoma, Mucoepidermoid; Carcinoma, Acinar Cell; Urethral Neoplasms; Prostatic Neoplasms; Solid tumours; Breast Neoplasms; Urinary Bladder Neoplasms; Salivary Gland Neoplasms; Colonic Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Stomach Neoplasms; Meningeal Carcinomatosis; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplastic Cells, Circulating; Ependymoma | Details |
Lapatinib Ditosylate Hydrate | GW-572016; GW-572016F; GW-2016 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | Tykerb, Tyverb, 泰立沙, Tykerb/Tyverb | Mainland China | Breast Neoplasms | Glaxosmithkline Ag | 2007-03-13 | Neoplasms, Gonadal Tissue; Carcinoma, Acinar Cell; Carcinoma, Mucoepidermoid; Colorectal Neoplasms; Astrocytoma; Gliosarcoma; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Brain metastases; Lung Neoplasms; Endometrial Neoplasms; Brain Neoplasms; Laryngeal Neoplasms; Gallbladder Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Neoplasm Metastasis; Tongue Neoplasms; Melanoma; Breast Neoplasms, Male; Carcinoma, Non-Small-Cell Lung; Neuroma, Acoustic; Pancreatic Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Ependymoma; Liver Neoplasms; Medulloblastoma; Stomach Neoplasms; Esophageal Neoplasms; Abdominal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Ovarian Epithelial; Solid tumours; Carcinoma, Verrucous; Glioblastoma; Salivary Gland Neoplasms; Neoplasms; Neurofibromatosis 2; Urinary Bladder Neoplasms; Carcinoma, Adenoid Cystic; Central Nervous System Neoplasms; Oligodendroglioma; Breast Neoplasms; Prost | Details |
Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Pharmaceutical Co Ltd | 泰瑞沙, Tagrisso | Mainland China | Carcinoma, Non-Small-Cell Lung | Astrazeneca Ab | 2015-11-13 | Uterine Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Brain metastases; Esophageal adenocarcinoma; Cholangiocarcinoma; Lymphoma; Glioma; Endometrial Neoplasms; Thyroid Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma of Lung; Liver Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rectal Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Skin Neoplasms; Colonic Neoplasms; Glioblastoma; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
Pyrotinib Maleate | HTI-1001; SHR-1258; BLTN | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妮 | Mainland China | Breast Neoplasms | Jiangsu Hengrui Medicine Co Ltd | 2018-08-12 | Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms | Details |
Neratinib Maleate | CAN-030; HKI-272; PF-0528767; WAY-179272; PB-272 | Approved | Pfizer Pharmaceuticals Ltd (China) | Nerlynx, 贺俪安 | Mainland China | Breast Neoplasms | Excella Gmbh & Co Kg | 2017-07-17 | Solid tumours; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung | Details |
Inetetamab | CMAB-302 | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | Cipterbin, 赛普汀 | Mainland China | Breast Neoplasms | Shanghai Cp Guojian Pharmaceutical Co Ltd | 2020-06-17 | Breast Neoplasms | Details |
Margetuximab | MGAH-22 | Approved | Macrogenics Inc | Margenza | United States | Breast Neoplasms | Macrogenics Inc | 2020-12-16 | Ovarian Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Trastuzumab biosimilar (Samsung Bioepis) | SB-3; AMT-901 | Approved | Samsung Bioepis Co Ltd | Samfenet, Ontruzant | United States | Breast Neoplasms; Stomach Neoplasms | Samsung Bioepis Co Ltd | 2017-11-15 | Stomach Neoplasms; Breast Neoplasms | Details |
Trastuzumab biosimilar (Synthon) | ABP-980 | Approved | Synthon Bv | Kanjinti | United States | Breast Neoplasms; Stomach Neoplasms | Amgen Inc | 2018-05-16 | Breast Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Endometrial Neoplasms; Esophageal adenocarcinoma; Uterine Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Glioma; Lymphoma; Colorectal Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Carcinoma, Intraductal, Noninfiltrating; Ovarian Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Colonic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Solid tumours; Liver Neoplasms | Details |
Trastuzumab biosimilar (Celltrion) | CT-P6; CT-P06 | Approved | Celltrion Inc | Herzuma | United States | Breast Neoplasms | Celltrion Inc | 2014-01-01 | Stomach Neoplasms; Breast Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) | Phase 1 Clinical | Shenzhen Main Luck Pharmaceuticals Inc | Breast Neoplasms | Details | |
Pertuzumab biosimilar (CTTQ) | TQB-2440 | Phase 3 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Recombinant humanized anti-HER2 antibody (Hisun Pharma) | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
JRF-103 | JRF103; JRF-103 | Phase 2 Clinical | Shenzhen Jinrui Foundation Biotechnology Co Ltd | Solid tumours | Details |
Trastuzumab biosimilar(Aprogen/Nichi-Iko) | AP-06 | Phase 3 Clinical | Nichi-Iko Pharmaceutical Co Ltd, Aprogen | Breast Neoplasms | Details |
Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) | Phase 1 Clinical | Baylor College Of Medicine, The Hospital For Sick Children, Texas Children'S Hospital, The Methodist Hosp Research Institute | Sarcoma | Details | |
SSGJ-706 | SSGJ-706 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
PM-3002 | PM-3002 | Phase 1 Clinical | Biotheus Inc | Details | |
99mTc- ADAPT6 | 99mTc- ADAPT6; ADAPT6; SNA-018 | Phase 1 Clinical | Uppsala University, Kth Royal Institute Of Technology | Breast Neoplasms | Details |
BAY-2701439 | BAY-2701439 | Phase 1 Clinical | Bayer AG | Neoplasms | Details |
TAA-013 | TAA-013 | Phase 3 Clinical | Tot Biopharm Co Ltd | Breast Neoplasms | Details |
HL-02 | HL-02 | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Breast Neoplasms | Details |
TGFBeta-resistant-HER2-EBV-CTLs | TGFBeta-resistant-HER2-EBV-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Neoplasms | Details |
Trastuzumab biosimilar (United BioPharma) | UB-921 | Phase 1 Clinical | United Biopharma Inc | Breast Neoplasms | Details |
IBPM002BZ (Inbiopro Solutions) | IBPM-002BZ | Clinical | Inbiopro Solutions | Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms | Details |
Trastuzumab biosimilar (Hualan Biological Engineering) | Phase 1 Clinical | Hualan Genetic Engineering Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details | |
IBPM003TZ (Inbiopro Solutions) | IBPM-003TZ | Clinical | Inbiopro Solutions | Breast Neoplasms | Details |
PB-357 | PB-357 | Phase 1 Clinical | Pfizer Inc | Neoplasms | Details |
Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Research Institute | Central Nervous System Neoplasms | Details | |
KSP-QRH-E3-IRDye800 | Phase 1 Clinical | University Of Michigan | Cholangiocarcinoma | Details | |
Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) | HS-630; HS630 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
SHR-A1201 | SHR-A1201 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Breast Neoplasms | Details |
Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) | Phase 2 Clinical | University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune | Breast Neoplasms | Details | |
AU-101 | AU-101 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma; Osteosarcoma; Breast Neoplasms | Details |
68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) | Phase 1 Clinical | Universite Libre De Bruxelles | Breast Neoplasms | Details | |
MX-402 | MX-402 | Phase 1 Clinical | Medvax Technologies | Stomach Neoplasms | Details |
Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) | LZM-005 | Phase 1 Clinical | Livzon Pharmaceutical Group Inc | Breast Neoplasms | Details |
Trastuzumab biosimilar (BioXpress) | BXT-2318; BX-2318 | Clinical | Bioxpress Therapeutics Sa | Stomach Neoplasms; Metastatic breast cancer | Details |
99m-Tc labeled anti-HER2 single domain antibody (NanoMab) | 99mTc-NM-02 | Phase 1 Clinical | Nanomab Technology Ltd | Breast Neoplasms | Details |
Pertuzumab biosimilar (Xuanzhu/SL) | KM-118; KM118; XZP-KM118 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd | Breast Neoplasms | Details |
SSGJ-612 | SSGJ-612 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details |
Pertuzumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Breast Neoplasms | Details | |
Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung | Details |
GB-251 | GB-251; NBT-828; GB221-NBT828 ADC-1 | Phase 1 Clinical | Genor Biopharma Co Ltd, Newbio Therapeutics Inc | Breast Neoplasms; Metastatic breast cancer | Details |
Puvitinib | Phase 1 Clinical | Suzhou Teligene Ltd | Solid tumours | Details | |
KY-1701 | KY-1701 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Breast Neoplasms | Details |
GB-235 | GB-235 | Phase 1 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
Pertuzumab biosimilar (Jushi Biopharmaceutical ) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details | |
Epertinib | S-222611 | Phase 2 Clinical | Shionogi & Co Ltd | Neoplasms | Details |
AU-105 | AU-105 | Phase 2 Clinical | Aurora Biopharma | Glioblastoma | Details |
99mTc-DARPinG3 | 99mTc-DARPinG3; 99mTc-DARPinG-3 | Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms | Details |
I-025-A | I-025-A | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) | HS-022 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Breast Neoplasms | Details |
HER2/neu cancer vaccine (University of Washington/Corixa/GSK) | University Of Washington | Details | |||
CP-724714 | CP-724714 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
Mubritinib | TAK-165 | Takeda Pharmaceutical Co Ltd | Details | ||
MBS-301 | MBS-301 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Sichuan University | Details | |||
MP-412 | AV-412; MP-412 | Mitsubishi Tanabe Pharma | Details | ||
BVAC-B vaccine (Cellid) | BVAC-B | Cellid Company | Details | ||
TAK-285 | TAK-285 | Takeda | Details | ||
BCD-147 | BCD-147 | Biocad | Details | ||
M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) | M-802 | Phase 1 Clinical | Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Breast Neoplasms | Details |
Recombinant anti-HER2 humanized monoclonal antibody complex | B-002 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Molecular Partners Ag | Details | ||
Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) | B-003 (Shanghai Pharma) | Phase 1 Clinical | Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Pharmaceuticals Holding Co Ltd | Breast Neoplasms | Details |
MEDI-4276 | MEDI-4276 | Medimmune Llc | Details | ||
RG-6148 | RG-6148; DHES-0815A | F. Hoffmann-La Roche Ltd | Details | ||
Hemay-022 | Hemay-022 | Phase 3 Clinical | Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd | Breast Neoplasms; Foodborne Diseases | Details |
DZD-1516 | DZD-1516 | Phase 1 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details | |
Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated | ZV0203; ZV203 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Zhejiang Zova Biotherapeutics Inc, Concortis Biosystems Corp | Solid tumours | Details |
Selatinib Ditosilate | QLNC-120 | Phase 2 Clinical | Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
AMX-3009 Maleate | AMX-3009; AMX3009马来酸 | Phase 1 Clinical | Anrun Medicine Technology (Suzhou) Co Ltd | Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms | Details |
BAT-1006 | BAT-1006 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
Pertuzumab biosimilar(EirGenix) | EG-1206A; EG-1206-A | Phase 1 Clinical | Eirgenix Inc | Breast Neoplasms | Details |
BC-004 | BC-004 | Phase 1 Clinical | Shandong Buchang Pharmaceuticals Co Ltd | Solid tumours; Breast Neoplasms | Details |
Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) | SIBP-01 | Phase 3 Clinical | Shanghai Institute Of Biological Products Co Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
IMM-2902 | IMM-2902 | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
Recombinant anti-HER2 subdomain II and subdomain IV humanized monoclonal antibody(Xuanzhu) | XZP-KM257; KM257/252; KM-257 | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd | Solid tumours | Details |
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) | Phase 1 Clinical | Solid tumours | Details | ||
NIP-142 | NIP-142 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
trastuzumab biosimilar (Hetero) | Ado-Trastuzumab biosimilar (Hetero) | Phase 3 Clinical | Hetero Drugs Ltd | Neoplasms | Details |
Trastuzumab biosimilar (BioIntegrator) | BI-Mab-03 | Phase 1 Clinical | Biointegrator Llc | Breast Neoplasms | Details |
TT-16 | TT-16 | Phase 1 Clinical | Tessa Therapeutics Ltd | Solid tumours | Details |
Trastuzumab biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Serum Institute Of India Ltd, Neuclone | Stomach Neoplasms; Breast Neoplasms | Details | |
MB-103 | MB-103 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioblastoma; Brain metastases | Details |
HER2(EQ)BBzeta/CD19 T cells (City of Hope) | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Glioma | Details | |
SPH-5030 | SPH-5030 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Solid tumours | Details |
ORIC-114 | ORIC-114 | Phase 1 Clinical | Voronoi | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
HER2 cancer vaccine (BioLife Science) | PEV-6; PEV-6A; IMU-131 | Phase 2 Clinical | Pevion Biotech Ltd | Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Neoplasms; Adenocarcinoma | Details |
MT-5111 | MT-5111 | Phase 1 Clinical | Molecular Templates Inc | Solid tumours | Details |
BDC-1001 | BDC-1001 | Phase 2 Clinical | Bolt Biotherapeutics Inc | Solid tumours | Details |
Iodine-131-SGMIB anti-HER2 monoclonal antibody | [131I]-SGMIB Anti-HER2-VHH1; 131I-SGMIB-anti-HER2-VHH1; Iodine-131-SGMIB-anti-HER2-VHH1; CAM-H2 | Phase 2 Clinical | Camel-Ids Nv | Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms | Details |
TAC01-HER2 | TAC01-HER2 | Phase 2 Clinical | Triumvira Immunologics Inc | Solid tumours | Details |
NeuCeptin | NeuCeptin | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Stomach Neoplasms; Breast Neoplasms | Details |
Anti-CD3-anti-HER2-activated T cells | Phase 2 Clinical | Transtarget | Breast Neoplasms; Prostatic Neoplasms | Details | |
Pertuzumab biosimilar (Qilu Pharmaceutical) | QL-1209 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Breast Neoplasms | Details |
AE-37/GP-2 vaccine | AE-37 (Generex Biotechnology Corporation) | Phase 2 Clinical | Generex Biotechnology Corp | Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
HER.CAR-CMV-specific-CTLs | HER.CAR-CMV-specific-CTLs | Phase 1 Clinical | Baylor College Of Medicine | Glioblastoma | Details |
4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Neoplasms; Lymphoma | Details | |
Autologous-HER2-specific-T-cells | Autologous-HER2-specific-T-cells | Phase 1 Clinical | Baylor College Of Medicine | Sarcoma; Brain Neoplasms | Details |
Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Breast Neoplasms | Details | |
Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) | Phase 1 Clinical | National Cancer Institute | Neoplasms; Breast Neoplasms; Adenocarcinoma; Neoplasm Metastasis | Details | |
ALT-P7 | HM2-MMAE; ALT-P7 | Phase 1 Clinical | Alteogen Inc | Stomach Neoplasms; Breast Neoplasms | Details |
Pertuzumab biosimilar(Hisun Pharm) | HS-627; HS627 | Phase 3 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd | Breast Neoplasms | Details |
TPIV-100 (TapImmune) | TPIV-100 | Phase 2 Clinical | Mayo Clinic | Carcinoma, Intraductal, Noninfiltrating; Breast Neoplasms; Breast Neoplasms, Male | Details |
HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania, National Cancer Institute | Breast Neoplasms | Details | |
CIDeCAR | Phase 1 Clinical | Bellicum Pharmaceuticals Inc, National Cancer Institute | Osteosarcoma; Sarcoma; Neuroblastoma; Melanoma | Details | |
89Zr-ss-Pertuzumab | Phase 1 Clinical | Genentech Inc | Breast Neoplasms; Metastatic breast cancer | Details | |
HER-2 Specific CAR T Cell | Phase 1 Clinical | Pediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital | Ependymoma | Details | |
HER2.taNK | NK-92/5.28.z | Phase 1 Clinical | Nantkwest Inc | Glioblastoma | Details |
Cinrebafusp alfa | PRS-343 | Phase 2 Clinical | Pieris Pharmaceuticals | Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms | Details |
99mTc-HPArk2 | 99mTc-HPArk2; 99-mTc-HPArk-2 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
Recombinant anti-HER2 antibody-Tub114 | DAC-001; DX126-262 | Phase 2 Clinical | Hangzhou Dac Biotech Company Ltd | Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
Pertuzumab biosimilar(Zydus Cadila) | ZRC-3277 | Phase 3 Clinical | Zydus Cadila | Breast Neoplasms | Details |
PLB-1004 | PLB-1004 | Phase 1 Clinical | Beijing Anshi Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
AB-201 (Artiva Biotherapeutics) | Phase 1 Clinical | Artiva Biotherapeutics Inc | Solid tumours | Details | |
ETBX-021 | ETBX-021 | Phase 2 Clinical | Nantbioscience Inc, Etubics Corp | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
CT-0508 | Phase 1 Clinical | Carisma Therapeutics Inc | Digestive System Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Squamous Cell; Carcinoma, Small Cell; Endometrial Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Ductal; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Inflammatory Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Stomach Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours | Details | |
SSGJ-705 | SSGJ-705 | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
MRG-002 | MRG-002 | Phase 2 Clinical | Shanghai Miracogen Inc | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
A-166 | A-166 | Phase 2 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Mouth Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Mucoepidermoid; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Urologic Neoplasms; Urinary Bladder Neoplasms; Lip Neoplasms; Laryngeal Neoplasms; Tonsillar Neoplasms; Lung Neoplasms; Tongue Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Cystadenocarcinoma, Mucinous; Liver Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Skin Neoplasms; Colonic Neoplasms; Rare Diseases; Carcinoma, Transitional Cell; Neoplasms | Details |
[89Zr]-Df-Trastuzumab | Phase 1 Clinical | University Of Alabama At Birmingham | Solid tumours; Neoplasms; Breast Neoplasms | Details | |
Runimotamab | BTRC-4017A; RG-6194 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Pertuzumab biosimilar(SL Pharma/Combio) | Phase 1 Clinical | Beijing Kangming Bio New Drug Development Co Ltd, Beijing Sl Pharmaceutical Co Ltd | Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details | |
FDA022 Antibody Drug Conjugate | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details | |
HLX-22 | AC-101; HLX-22 | Phase 2 Clinical | Shanghai Henlius Biotech Co Ltd | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
GQ-1005 | GQ-1005; GQ1005 | Phase 1 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
anti-HER2 ADC (Pfizer) | PF-06804103 | Phase 2 Clinical | Pfizer Inc | Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms | Details |
YH-32367 | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
EX-101 | EX-101; EX101 | Phase 1 Clinical | Guangzhou ASM Biomedical Technology Co Ltd | Solid tumours | Details |
XZP-5209 | XZP-5209 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung | Details | |
Tarloxotinib Bromide | PR-610; TH-4000; SN-33999 | Phase 2 Clinical | Threshold | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
DB-1303 | DB-1303 | Phase 2 Clinical | Duality Biologics Co Ltd | Solid tumours; Neoplasm Metastasis | Details |
JSKN-003 | JSKN-003 | Phase 1 Clinical | Alphamab Oncology | Solid tumours; Neoplasms | Details |
BB-1701 | BB-1701 | Phase 2 Clinical | Baili Sikang Biomedicine (Hangzhou) Co Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
ORM-5029 | ORM-5029 | Phase 1 Clinical | Orum Therapeutics Inc | Solid tumours; Breast Neoplasms | Details |
HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) | GLSI-100 | Phase 3 Clinical | Antigen Express Inc, Norwell Inc | Breast Neoplasms | Details |
SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Neoplasms; Glioblastoma; Breast Neoplasms; Brain Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
ZN-A-1041 | ZN-A-1041 | Phase 1 Clinical | Suzhou Zanrong Pharmaceutical Technology Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms | Details |
DP-303c | DP-303c; DP303c | Phase 2 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
BAY-2927088 | BAY-2927088; BAY2927088 | Phase 1 Clinical | Bayer Healthcare Company Ltd, Bayer AG | Carcinoma, Non-Small-Cell Lung | Details |
AIP-303 | AIP-303 | Phase 2 Clinical | Advanced Imaging Projects | Breast Neoplasms | Details |
Larotinib Mesylate | Z-650 | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma | Details |
Sunvozertinib | DZD-9008 | Phase 2 Clinical | Dizal (Jiangsu) Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung | Details |
KSP-910638-G | KSP-910638G; KSP-910638-G | Phase 1 Clinical | University Of Michigan | Gastrointestinal Neoplasms | Details |
TAS-2940 | TAS-2940 | Phase 1 Clinical | Taiho Oncology Inc | Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Solid tumours; Breast Neoplasms | Details |
99mTc-MIRC213 | 99-mTc-MIRC-213 | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms | Details |
99mTc-MIRC208 | Clinical | Beijing Cancer Hospital | Neoplasms | Details | |
Gancotamab | MM-302 | Phase 2 Clinical | Merrimack Pharmaceuticals Inc | Ovarian Neoplasms; Breast Neoplasms | Details |
FCN-411 | FCN-411 | Phase 2 Clinical | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Pirotinib Hydrochloride | KBP-5209 | Phase 2 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Solid tumours; Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Trastuzumab biosimilar (Alteogen) | ALT-L2; ALT-02; QL-1701; ALT-LS2 | Phase 3 Clinical | Alteogen Inc | Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms | Details |
ARV-471 | ARV-471; PF-07850327 | Phase 2 Clinical | Arvinas Inc | Breast Neoplasms | Details |
Varlitinib Ditosylate | QBT-01; ARRY-543; SPS-4370; ASLAN-001; ARRY-334543 | Phase 2 Clinical | Array Biopharma | Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Bile Duct Neoplasms | Details |
SHR-A1811 | SHR-A1811 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; HR-positive breast cancer; Carcinoma, Non-Small-Cell Lung | Details |
[18F]GE-226 | ABY-002; ABY-025; ABY-0125; 68GaABY025; GE-226; [68Ga]-ABY-025; GE-226-[18F]; [111]In-ABY-025; ABY-025-[68Ga]; ABY-025-[111In]; Gallium-68-ABY-025; Indium-111-ABY-025; Fluorine-18-GE-226 | Phase 3 Clinical | Affibody Ab | Breast Neoplasms | Details |
ACE-1702 | ACE-1702 | Phase 1 Clinical | Acepodia Taiwan Subsidiary | Solid tumours; Stomach Neoplasms; Metastatic breast cancer; Neoplasm Metastasis | Details |
GQ-1001 | GQ-1001 | Phase 2 Clinical | GeneQuantum Healthcare (Suzhou) Co Ltd | Solid tumours; Breast Neoplasms; Metastatic breast cancer | Details |
IAH-0968 | IAH-0968; IAH0968 | Phase 2 Clinical | Shenghe (China) Biopharmaceutical Co Ltd | Solid tumours; Biliary Tract Neoplasms; Colorectal Neoplasms | Details |
Pertuzumab biosimilar (Shanghai Henlius Biotech) | HLX-11 | Phase 3 Clinical | Shanghai Henlius Biotech Co Ltd | Breast Neoplasms; Metastatic breast cancer | Details |
Zanidatamab zovodotin | ZW-49 | Phase 1 Clinical | Zymeworks Inc | Neoplasms | Details |
XMT-2056 | XMT-2056 | Phase 1 Clinical | Mersana Therapeutics Inc | Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Zenocutuzumab | MCLA-128 | Phase 2 Clinical | Merus Nv | Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Anbenitamab | KN-026 | Phase 3 Clinical | Suzhou Alphamab Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Lymphoma; Gastrointestinal Neoplasms | Details |
Coprelotamab | GB-221 | Phase 3 Clinical | Genor Biopharma Co Ltd | Breast Neoplasms | Details |
Trastuzumab monomethyl auristatin F | FS-1502; LCB14-0110; LCB-14-0110 | Phase 2 Clinical | Legochembio | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Trastuzumab biosimilar (Hanwha Biologics) | HD-201 | Phase 3 Clinical | Hanwha Biologics | Kidney Neoplasms; Breast Neoplasms | Details |
Fidasimtamab | IBI-315 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
ARX-788 | ARX-788; NCB-001 | Phase 3 Clinical | Ambrx Inc | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms | Details |
Zanidatamab | ZW-25 | Phase 3 Clinical | Zymeworks Inc | Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Esophageal adenocarcinoma; Endometrial Neoplasms; Carcinosarcoma; Gastrointestinal Neoplasms | Details |
DF-1001 | DF-1001 | Phase 2 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
This web search service is supported by Google Inc.